These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1583321)

  • 21. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults.
    Cryz SJ; Levine MM; Kaper JB; Fürer E; Althaus B
    Vaccine; 1990 Dec; 8(6):577-80. PubMed ID: 2087879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.
    McCarty JM; Lock MD; Bennett S; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2019 Mar; 37(11):1389-1397. PubMed ID: 30772070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
    Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF
    Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.
    Kollaritsch H; Furer E; Herzog C; Wiedermann G; Que JU; Cryz SJ
    Infect Immun; 1996 Apr; 64(4):1454-7. PubMed ID: 8606118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
    Levine MM; Kaper JB; Herrington D; Ketley J; Losonsky G; Tacket CO; Tall B; Cryz S
    Lancet; 1988 Aug; 2(8609):467-70. PubMed ID: 2900401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.
    Lagos R; Fasano A; Wasserman SS; Prado V; San Martin O; Abrego P; Losonsky GA; Alegria S; Levine MM
    J Infect Dis; 1999 Nov; 180(5):1709-12. PubMed ID: 10515838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
    Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
    J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.
    Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB
    Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.
    Cryz SJ; Levine MM; Losonsky G; Kaper JB; Althaus B
    Infect Immun; 1992 Sep; 60(9):3916-7. PubMed ID: 1500200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect.
    Wasserman SS; Kotloff KL; Losonsky GA; Levine MM
    Am J Epidemiol; 1993 Dec; 138(11):988-93. PubMed ID: 8256784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults.
    Muhsen K; Sow SO; Tapia MD; Haidara FC; Reymann M; Asato V; Chen WH; Pasetti MF; Levine MM
    Sci Rep; 2020 Oct; 10(1):16871. PubMed ID: 33037244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States.
    McCarty JM; Cassie D; Bedell L; Lock MD; Bennett S
    Am J Trop Med Hyg; 2021 Apr; 104(5):1758-1760. PubMed ID: 33819178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
    Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
    Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
    McCarty JM; Gierman EC; Bedell L; Lock MD; Bennett S
    Am J Trop Med Hyg; 2020 Jan; 102(1):48-57. PubMed ID: 31769402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.